Litcius/Paper detail

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant <i>Enterobacterales</i>

Olga Lomovskaya, Debora Rubio-Aparicio, Ruslan Tsivkovski, Jeff Loutit, Michael Dudley

2021Antimicrobial Agents and Chemotherapy28 citationsDOIOpen Access PDF

Abstract

QPX7728 is a cyclic boronate ultrabroad-spectrum beta-lactamase inhibitor, with potent activity against both serine beta-lactamases and metallo-beta-lactamases. QPX7728 can be delivered systemically by the intravenous (i.v.) or oral route of administration.

Topics & Concepts

Beta-Lactamase InhibitorsChemistryBeta-lactamaseCephalosporinEffluxAntibacterial agentBETA (programming language)AntibioticsPharmacologyBiochemistryMedicineEscherichia coliComputer scienceProgramming languageGeneAntibiotic Resistance in BacteriaAntimicrobial Resistance in StaphylococcusBacterial Identification and Susceptibility Testing
The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant <i>Enterobacterales</i> | Litcius